Fluoxetine in the management of major depressive disorder in children and adolescents: A meta-analysis of randomized controlled trials
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2020-12-01
Metadata
Show full item recordAbstract
Fluoxetine is a serotonin specific reuptake inhibitor anti-depressant and is the only approved pharmacological treatment for major depressive disorder (MDD) in children and adolescent. We searched the published randomized controlled-trials (RCT) to review fluoxetine efficacy and tolerability using the databases PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials for fluoxetine role in managing MDD in children and adolescents. A meta-analysis was conducted using the identified 7 clinical trials to assess efficacy using the outcomes: Children’s Depression Rating Scale-Revised (CDRS-R), Clinical Global Impressions – Severity of Illness (CGI-S) and Clinical Global Impressions – Improvement (CGI-I) response rate. The risk of discontinuation due to adverse effects and common side effects were examined. The mean difference in change from baseline for CDRS-R was -2.72 [95% Confidence Interval (CI) -3.96, -1.48] favouring fluoxetine treatment (p<0.001). Similarly, mean difference for CGI-S was -0.21 [95% CI -0.36, -0.06]. The risk ratio (RR) of discontinuing due to adverse events was 0.98 [95% CI 0.54, 1.83], with RR for headache side effects 1.34 [95% CI 1.03, 1.74] and rash 2.6 [95% CI 1.32, 5.14]. Fluoxetine demonstrates significant improvements in symptom intensity control in young patients suffering from MDD and is considered well-tolerated with similar rates of trials discontinuation; however, fluoxetine was associated with a higher risk of headache and rash side effects. These findings will guide psychiatrists and pharmacists in their clinical role for supporting the care of young mental health patients.Citation
Antoun Reyad, A., Plaha, K., Girgis, E. and Mishriky, R. (2020) Fluoxetine in the management of major depressive disorder in children and adolescents: A meta-analysis of randomized controlled trials, Hospital Pharmacy (in press)Publisher
Thomas Land Publishers Inc.Journal
Hospital PharmacyAdditional Links
https://journals.sagepub.com/home/hpxaType
Journal articleLanguage
enDescription
This is an accepted manuscript of an article to be published by SAGE in Hospital Pharmacy (in press). The accepted version of the publication may differ from the final published version.ISSN
0018-5787Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/